Treatment of Neuropathic Pain After Nerve Block

First-Line Pharmacological Options

The American Academy of Neurology recommends combination therapy using gabapentin or pregabalin with either a tricyclic antidepressant or SSNRI for patients experiencing neuropathic pain after nerve block, as it provides the most effective pain relief 1, 2, 3
Calcium channel α2-δ ligands, such as pregabalin or gabapentin, are FDA-approved for neuropathic pain and should be initiated at low doses and gradually titrated to effective dosage 4
Tricyclic antidepressants (TCAs), specifically secondary amine TCAs like nortriptyline or desipramine, are preferred over tertiary amines due to fewer anticholinergic side effects 4
Selective serotonin norepinephrine reuptake inhibitors (SSNRIs), such as duloxetine (60mg daily), have shown consistent efficacy in neuropathic pain with better tolerability than TCAs 4, 5
Topical lidocaine can be used alone or in combination with systemic medications for localized peripheral neuropathic pain 4

Combination therapy with gabapentin and nortriptyline has proven superior to either medication alone 3, 6
Gabapentin and extended-release morphine combination requires lower doses of both medications and provides better pain relief than monotherapy 1, 2
Pregabalin and topical 5% lidocaine is an effective combination for peripheral neuropathic pain 2
Pregabalin and opioid combination has shown improved pain relief at lower doses than either medication alone 3

Initial therapy should start with either pregabalin/gabapentin or a TCA/SSNRI based on comorbidities, with pregabalin/gabapentin preferred for patients with sleep disturbance and TCA/SSNRI preferred for patients with depression 2, 4
Inadequate response after 4-6 weeks should be addressed by adding a second first-line agent, combining gabapentinoid with TCA/SSNRI 1, 2, 3
Continued inadequate response should be addressed by considering adding topical agents for localized pain or low-dose opioids for severe pain 4

Titration is essential to minimize side effects, starting with low doses and gradually increasing as needed 4
Opioids should not be relied upon solely for pain management due to significant risks associated with long-term use 4
Treatment duration is crucial, as most clinical trials are short (≤3 months), but neuropathic pain often requires long-term management 7
Response variability is a consideration, as not all neuropathic pain conditions respond equally to the same treatments, with some conditions like chemotherapy-induced neuropathy being more refractory 8